Avidity Biosciences, Inc. (RNA)
After hours:
| Previous close | 28.72 |
| Open | 28.83 |
| Bid | 29.46 x 300 |
| Ask | 29.56 x 300 |
| Day's range | 28.41 - 29.58 |
| 52-week range | 4.82 - 30.54 |
| Volume | |
| Avg. volume | 1,194,417 |
| Market cap | 2.821B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.96 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 45.25 |
PR NewswireAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatm
PR NewswireAvidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
- PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:
